Clinical Commissioning Policy: Clinical Commissioning Policy:

First Page		Document Content
Date: 2014-08-12 08:05:41 Medicine Immunosuppressants Autoimmune diseases Neurological disorders Glatiramer acetate Natalizumab Fingolimod McDonald criteria Interferon Immunology Multiple sclerosis Immune system		Clinical Commissioning Policy: Clinical Commissioning Policy: Add to Reading List Source URL: www.england.nhs.uk Download Document from Source Website File Size: 523,92 KB Share Document on Facebook

	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio DocID: 1qn6Z - View Document
	Stellungnahme der AkdÄ zur Nutzenbewertung von Fingolimod (neues Anwendungsgebiet) DocID: 1n48S - View Document
	Rote-Hand-Brief zu Gilenya® (Fingolimod) DocID: 1h06f - View Document
	Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators DocID: 1fWCE - View Document
	Bijlage bij email betreffende vergoeding fingolimod juliArtikel uit MenSen nr. 4 Samenvatting aanvullende voorwaarden zoals is overeengekomen op 4 juni 2013 met CVZ, VWS, zorgverzekeraars, MS Vereniging Nederland, DocID: 1ea9n - View Document